SCYX vs. KRON, KZR, EQ, HCWB, IMMX, RPHM, MURA, EGRX, LTRN, and GANX
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Kronos Bio (KRON), Kezar Life Sciences (KZR), Equillium (EQ), HCW Biologics (HCWB), Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Mural Oncology (MURA), Eagle Pharmaceuticals (EGRX), Lantern Pharma (LTRN), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical preparations" industry.
SCYNEXIS (NASDAQ:SCYX) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
SCYNEXIS currently has a consensus price target of $15.00, indicating a potential upside of 892.65%. Kronos Bio has a consensus price target of $4.25, indicating a potential upside of 324.36%. Given SCYNEXIS's higher probable upside, equities research analysts plainly believe SCYNEXIS is more favorable than Kronos Bio.
SCYNEXIS has a net margin of 47.84% compared to Kronos Bio's net margin of -1,791.87%. SCYNEXIS's return on equity of 156.27% beat Kronos Bio's return on equity.
SCYNEXIS received 488 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 65.38% of users gave Kronos Bio an outperform vote.
SCYNEXIS has higher revenue and earnings than Kronos Bio. Kronos Bio is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 4.4% of SCYNEXIS shares are owned by company insiders. Comparatively, 23.4% of Kronos Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
SCYNEXIS has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
In the previous week, SCYNEXIS and SCYNEXIS both had 2 articles in the media. SCYNEXIS's average media sentiment score of 0.53 beat Kronos Bio's score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.
Summary
SCYNEXIS beats Kronos Bio on 11 of the 16 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
